Medicine News Car T Cell Therapy Reaches Beyond Cancer Penn Medicine

Dual-target CAR T cell therapy shrinks tumors in aggressive brain cancer

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ... Read More

Engineered CAR-T cells show promise against glioblastoma in preclinical models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer. Read More

Expanding CAR T-Cell Access With Broader Criteria and Real-World Data: Clark Alsfeld, MD

At the Institute for Value-Based Medicine ® event in New Orleans, Louisiana, on November 4, Clark Alsfeld, MD, a hematology and oncology specialist at Ochsner MD Anderson, spoke about the availability ... Read More

Dual-Target CAR-T Cell Therapy Slows Glioblastoma Tumors in Phase I Trial

Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ... Read More

Next-generation CAR T cells could expand solid cancer treatment options

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ... Read More

CAR-T cell therapy is revolutionising cancer treatment – here’s how it works

Recreation of CAR-T cells attacking a cancerous melanoma cell. Nemes Laszlo/Shutterstock Personalised medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most ... Read More

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ... Read More

Penn professor Carl June discusses medical innovation award, CAR-T cell research in DP interview

Penn Medicine professor Carl June was recently awarded the Broermann Medical Innovation Award 2025 for his work on utilizing CAR-T cells in cancer therapy. Modifying T-cells with chimeric antigen ... Read More

Scientists reawaken exhausted T cells to supercharge cancer immunity

Researchers discovered a way to keep T cells from wearing out during the fight against cancer, and the approach could make immune-based treatments far more powerful. They found that tumors use a ... Read More